November 28, 2017 @ 7:51 pm | Breaking News, INCY, Jubak Picks Portfolio, Update |
Maybe you didn’t even know there was a biotech dip. If all you’ve been following in the sector is a stock like Nektar Therapeutics (NKTR), a Jubak Picks member (and the call options are a holding in my Volatility Portfolio), you’re likely to respond...
November 18, 2016 @ 7:32 pm | IONS, Jubak Picks Portfolio, Update |
Sometimes the importance of a clinical trial extends way beyond the specific drug under study. That’s the case with the Phase II data recently released by Ionis for FIXRx. The trial did show efficacy in the treatment of kidney disease. But the most important...